Irish contractor John Paul Construction has completed construction of a continuous glucose monitor manufacturing facility in Athenry for San Diego-based Dexcom, marking a significant milestone in the US medical device company's $325 million (€298 million) investment in the west of Ireland.

The completion was announced by John Paul Construction via LinkedIn, which described the project as a 25-month programme to deliver a state-of-the-art manufacturing and office development for the Nasdaq-listed CGM developer.

The facility includes a highly technical production environment featuring cleanrooms, supporting laboratory and engineering spaces, and a four-storey office building. Once operational, it will manufacture Dexcom's real-time CGMs, including the latest-generation G7 device.

In its LinkedIn post, John Paul Construction said: "Dexcom has been a valued client throughout, and we appreciate the trust placed in us to deliver this significant investment. We would like to thank the design team, our project partners and the wider site team for their commitment and professionalism in bringing this project to completion."

Dexcom broke ground on the Athenry site in January 2024, following the announcement of its investment plans in May 2023. The company described the commitment as one of the largest single private sector investments ever made in the west of Ireland, with more than 1,000 jobs expected to follow once the plant is operational.

The facility is Dexcom's first manufacturing site outside the United States, reinforcing Ireland's position as a hub for medtech production. Abbott opened its FreeStyle Libre manufacturing plant in Kilkenny in April 2024.

View the complete report for further details on the Athenry facility and Dexcom's Irish investment.